Given A -41.58% Drop From High, Can Global Blood Therapeutics Inc. (NASDAQ: GBT) Quickly Recover? – Marketing Sentinel
Home  »  Technologies   »  Given A -41.58% Drop From High, Can Global Blood T...

Given A -41.58% Drop From High, Can Global Blood Therapeutics Inc. (NASDAQ: GBT) Quickly Recover?

During the last session, Global Blood Therapeutics Inc. (NASDAQ:GBT)’s traded shares were 1.72 million, with the beta value of the company hitting 1.04. At the end of the trading day, the stock’s price was $28.74, reflecting an intraday gain of 0.56% or $0.16. The 52-week high for the GBT share is $40.69, that puts it down -41.58 from that peak though still a striking 24.67% gain since the share price plummeted to a 52-week low of $21.65. The company’s market capitalization is $1.67B, and the average trade volume was 1.36 million shares over the past three months.

Global Blood Therapeutics Inc. (GBT) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.90. GBT has a Sell rating from 0 analyst(s) out of 22 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 17 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$1.18.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Global Blood Therapeutics Inc. (NASDAQ:GBT) trade information

Global Blood Therapeutics Inc. (GBT) registered a 0.56% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.56% in intraday trading to $28.74 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 28.88%, and it has moved by 5.16% in 30 days. Based on these gigs, the overall price performance for the year is -20.21%.

The consensus price target of analysts on Wall Street is $58.65, which implies an increase of 51.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $31.00 and $102.00 respectively. As a result, GBT is trading at a discount of -254.91% off the target high and -7.86% off the low.

Global Blood Therapeutics Inc. (GBT) estimates and forecasts

Statistics show that Global Blood Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Global Blood Therapeutics Inc. (GBT) shares have gone down -8.06% during the last six months, with a year-to-date growth rate more than the industry average at 3.53% against 0.60. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -5.40% this quarter and then jump 2.70% in the quarter after that. In the rating firms’ projections, revenue will increase 42.60% compared to the previous financial year.

Revenue for the current quarter is expected to be $64.52 million as predicted by 20 analyst(s). Meanwhile, a consensus of 20 analyst(s) estimates revenue growth to $73.78 million by the end of Sep 2022.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -14.20%. While earnings are projected to return -19.30% in 2022, the next five years will return 37.00% per annum.

GBT Dividends

Global Blood Therapeutics Inc. is due to release its next quarterly earnings between February 22 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Global Blood Therapeutics Inc. (NASDAQ:GBT)’s Major holders

Global Blood Therapeutics Inc. insiders own 2.59% of total outstanding shares while institutional holders control 106.61%, with the float percentage being 109.44%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 303 institutions own stock in it. As of Dec 30, 2021, the company held over 5.99 million shares (or 9.21% of all shares), a total value of $175.42 million in shares.

The next largest institutional holding, with 5.48 million shares, is of Janus Henderson Group PLC’s that is approximately 8.42% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $160.49 million.

Also, the Mutual Funds coming in first place with the largest holdings of Global Blood Therapeutics Inc. (GBT) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Jan 30, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 2.24 million shares. This amounts to just over 3.44 percent of the company’s overall shares, with a $64.52 million market value. The same data shows that the other fund manager holds slightly less at 1.83 million, or about 2.81% of the stock, which is worth about $53.6 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]